The stock of pharma major Zydus Lifesciences hit lifetime highs this week and has gained 40 per cent over the last three months. More than half the gains for the stock came in the last one month.
The company’s December quarter results earlier this month were better than Street estimates on the back of higher gross margins and a strong showing in the domestic formulations segment. This, coupled with a strong US pipeline and investments in multiple medium-term opportunities, has kept investor sentiment positive for the stock.
Consolidated revenues for the company were up by 6 per cent and was led by